Search clinical trials for: Influenza Virus Vaccine USP Quadrivalent

Total 41688 results

National Institute of Allergy and Infectious Diseases...

Completed

Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4

Influenza | Influenza Immunisation | Avian Influenza

United States
Codagenix, Inc

Completed

Safety Study of Live Attenuated Influenza Vaccine, CodaVax

Influenza

Australia
Seqirus

Completed

Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults

Influenza, Human

United States
National Institute of Allergy and Infectious Diseases...

Completed

Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine

Influenza | Influenza Immunisation

United States
Seqirus

Completed

Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age

Influenza

Turkey, Philippines, Thailand, Malaysia, Lithuania, Colombia, Czechia, Estonia, Bulgaria, Latvia, Poland, Romania
Medicago

Completed

Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy Adults

RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases

United States, Canada
Medicago

Completed

Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in Adults

RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases

United States
Il-Yang Pharm. Co., Ltd.

Completed

Immunogenicity and Safety for 'IL-YANG Quadrivalent Influenza Vaccine' in Healthy Korean Children and Adolescents

Influenza, Human

Korea, Republic of
SK Chemicals Co., Ltd.

Completed

Immunogenicity and Safety of Quadrivalent Influenza Vaccine (NBP607-QIV) in Adults and Elderly Subjects

Influenza
Emory University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response (HIPCVAX-010S)

Influenza A Subtype H5N1 Infection

United States
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Genetic and Environmental Factors in the Response to Influenza Vaccination (SLVP028)

Healthy | Influenza

United States
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection (SLVP030)

Healthy | Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Sanofi Pasteur Quadrivalent Intradermal Influenza Vaccine Pregnancy Registry

Pregnancy | Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry

Pregnancy | Influenza

United States
MedImmune LLC

Completed

D2560C00015 FluMist Annual Safety Study 2018

Healthy | Influenza

United States
Medicago

Completed

Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in Adults

RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases

United States
Laboratorios Liomont
EPIC Research CRO; ILS Clinical Research; Q Square Solutions

Completed

Evaluation of a Recombinant Quadrivalent Influenza Vaccine Versus a Marketed Quadrivalent Inactivated Influenza Vaccine in Children 3 to 17.

Influenza, Human

Mexico
Medicago

Completed

Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal VLP Quadrivalent Influenza Vaccine in the Elderly Population

RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases

Canada
Medicago

Completed

Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adults

RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases

United States, Canada
Medigen Vaccine Biologics Corp.

Completed

A Study to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine

Influenza

Taiwan
Sinovac Biotech Co., Ltd

Completed

Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (7.5μg/0.25ml)

Seasonal Influenza

China
Sinovac Biotech Co., Ltd

Completed

Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (15µg/0.5ml)

Seasonal Influenza

China
NPO Petrovax

Completed

Safety, Reactogenicity, Immunogenicity, and Efficacy of Quadrivalent Inactivated Subunit Influenza Vaccine Grippol® Quadri and Trivalent Inactivated Polymer-Subunit Vaccine Grippol® Plus in Volunteers

Influenza

Russian Federation
Merck Sharp & Dohme LLC

Completed

Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041)

HPV Infections
Kameda Medical Center
Merck Sharp & Dohme LLC; PPD; Osaka University

Completed

The Immunogenicity of Simultaneous Administration of Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Vaccine

Influenza | Pneumococcal Pneumonia

Japan
Seqirus

Completed

A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.

Influenza, Human

United States
MedImmune LLC
AstraZeneca

Completed

Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 Season (FluMist)

Healthy | Influenza

United States
MedImmune LLC
AstraZeneca

Completed

Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age (FluMist)

Healthy | Influenza

United States
Vaccitech (UK) Limited
University of Oxford

Terminated

Improved Novel VaccIne CombinaTion InflUenza Study (INVICTUS)

Influenza

United Kingdom
Merck Sharp & Dohme LLC

Completed

Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants ≥50 Years of Age (V211-062)

Herpes Zoster
GlaxoSmithKline

Completed

An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children

Influenza

Spain, Poland, Philippines, Thailand, Belgium, United Kingdom, Czechia, Bangladesh, Dominican Republic, Honduras, Lebanon, Turkey, India
GlaxoSmithKline

Completed

A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults

Influenza

United States, Canada, Mexico
GlaxoSmithKline

Completed

A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Children

Influenza

Spain, Taiwan, Canada, United States, Mexico
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine When Administered in Children Who Previously Participated in Study 115345

Influenza

Spain, Czechia, United Kingdom, Poland
GlaxoSmithKline

Completed

A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older

Influenza

Canada
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age

Influenza

United States, Mexico
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine, Fluarix/Influsplit Tetra® (2013/2014 Season), in Adults 18 Years of Age and Older

Influenza

Germany
GlaxoSmithKline

Completed

Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of Age

Influenza

United States
GlaxoSmithKline

Completed

A Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine in Children

Influenza

Thailand, Bangladesh, Dominican Republic, Honduras, Lebanon, Panama, Philippines, Turkey
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of a GSK Influenza Vaccine Candidate in Adults.

Influenza

Czechia
GlaxoSmithKline

Completed

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK2321138A) Manufactured Using a New Process in Adults and Children

Influenza

United States, Germany, Poland, Spain, Czechia, Bangladesh, France
Seqirus

Completed

A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age

Influenza, Human

United States
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older

Herpes Zoster

Germany, Canada, United States
GlaxoSmithKline

Completed

Evaluation of the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine Influsplit™ Tetra (Fluarix™ Tetra) (GSK2321138A) When Co-administered With Pneumovax™ 23 in Adults 50 Years of Age and Older

Influenza

Belgium, France
Sanofi Pasteur, a Sanofi Company

Completed

A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Withdrawn

Safety and Effectiveness of a Seasonal Live Attenuated Influenza Vaccine in a Human Challenge Model of Infection With Wild-type (wt) Influenza A/California/2009 (H1N1)-Like Virus

Influenza, Human

United States
University of Colorado, Denver
MedImmune LLC

Completed

Shedding, Immunogenicity and Safety of Quadrivalent Live Intranasal Influenza Vaccine (QLAIV) in HIV-infected Children and Young Adults (QLAIV)

Human Immunodeficiency Virus (HIV)

United States
SK Chemicals Co., Ltd.

Completed

Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children Aged 6~35 Months

Influenza, Human

Korea, Republic of
Protein Sciences Corporation

Completed

Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age

Influenza

United States
GlaxoSmithKline

Completed

Immunogenicity and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra (2015 Season Southern Hemisphere) in Adults 18 Years of Age and Above

Influenza

Brazil

3

Subscribe